Efficacy of Panobinostat for the Treatment of Multiple Myeloma

Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myeloma, in patients who have received at least two pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Kastritis, Efstathios, Gavriatopoulou, Maria, Terpos, Evangelos, Dimopoulos, Meletios Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201625/
https://www.ncbi.nlm.nih.gov/pubmed/32411240
http://dx.doi.org/10.1155/2020/7131802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201625/
https://www.ncbi.nlm.nih.gov/pubmed/32411240
http://dx.doi.org/10.1155/2020/7131802

Ejemplares similares